Literature DB >> 7927918

Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines.

V Zabrenetzky1, C C Harris, P S Steeg, D D Roberts.   

Abstract

Thrombospondin (TSP) is a member of a family of extracellular matrix glycoproteins that may participate in multiple aspects of the metastatic cascade. We report an inverse correlation of steady-state Thbs-1 mRNA and protein expression with malignant progression among murine melanoma and human lung and breast carcinoma cell lines. Murine K-1735 melanoma cell lines of low metastatic potential, including K-1735 lines transfected with the murine nm23-1 cDNA, expressed higher TSP levels than related highly metastatic lines. In a model system of lung carcinoma malignant progression, immortalized human bronchial epithelial cells expressed higher TSP levels than v-Ki-ras, v-Ha-ras or n-ras transfectants, which in turn expressed higher TSP levels than tumor-derived, more aggressive variants. Among 3 unrelated breast carcinoma cell lines, Thbs-1 steady-state mRNA levels were greater in the 2 non-metastatic lines than the metastatic line. Our data show that malignant progression in some cell lines is associated with reduced TSP expression. The suppressive effects of nm23-1 transfection on metastatic potential are also associated with increased TSP expression; ras transfection, which results in increased tumorigenesis, is associated with decreased TSP expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927918     DOI: 10.1002/ijc.2910590209

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  50 in total

Review 1.  Posttranscriptional regulation of cancer traits by HuR.

Authors:  Kotb Abdelmohsen; Myriam Gorospe
Journal:  Wiley Interdiscip Rev RNA       Date:  2010-05-06       Impact factor: 9.957

2.  Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.

Authors:  A J Rice; M A Steward; C M Quinn
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

Review 3.  Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast.

Authors:  A Rice; C M Quinn
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

4.  Effects of polyamine synthesis inhibitors on primary tumor features and metastatic capacity of human breast cancer cells.

Authors:  Andrea Manni; Sharlene Washington; Xin Hu; James W Griffith; Richard Bruggeman; Laurence M Demers; David Mauger; Michael F Verderame
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

5.  Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.

Authors:  Ernest S Han; Robert A Burger; Kathleen M Darcy; Michael W Sill; Leslie M Randall; Dana Chase; Basmina Parmakhtiar; Bradley J Monk; Benjamin E Greer; Patrick Connelly; Koen Degeest; John P Fruehauf
Journal:  Gynecol Oncol       Date:  2010-09-25       Impact factor: 5.482

6.  Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.

Authors:  O Straume; L A Akslen
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

7.  Thrombospondins: from structure to therapeutics.

Authors:  D D Roberts
Journal:  Cell Mol Life Sci       Date:  2008-03       Impact factor: 9.261

8.  Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor.

Authors:  J C Rodriguez-Manzaneque; T F Lane; M A Ortega; R O Hynes; J Lawler; M L Iruela-Arispe
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

Review 9.  Differentiation and cancer in the mammary gland: shedding light on an old dichotomy.

Authors:  O W Petersen; L Rønnov-Jessen; V M Weaver; M J Bissell
Journal:  Adv Cancer Res       Date:  1998       Impact factor: 6.242

10.  Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.

Authors:  Jeff S Isenberg; Fuminori Hyodo; Lisa A Ridnour; Caitlin S Shannon; David A Wink; Murali C Krishna; David D Roberts
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.